Korean J Health Promot.  2021 Mar;21(1):8-16. 10.15384/kjhp.2021.21.1.8.

Impact of a Doctor's Verbal Recommendation on Pneumococcal 13-Valent Conjugate Vaccine among High-Risk Patients for Pneumonia in a Primary Care Setting

• Kim J
• Lee S
• Kim JS

• KMID: 2514113
• DOI: http://doi.org/10.15384/kjhp.2021.21.1.8

Abstract

Background
Streptococcus pneumoniae is the main bacterial pathogen of community-acquired pneumonia in Korea. This study aimed to enhance the vaccination rate by evaluating the effectiveness of current methods of recommendation.
Methods
A retrospective analysis of the medical records of 143 patients with high risk of pneumonia among first-visit outpatients was conducted. High-risk patients for pneumonia are defined by the U.S. Advisory Committee on Immunization Practices. One hundred and twenty-seven patients, excluding 16 with pneumococcal 13-valent conjugate vaccination (PCV13) history prior to the first visit, were divided into three groups according to the method of vaccination recommendation: banner (B) group; banner+brochure (B+Br) group; banner+brochure+doctor's recommendation (B+Br+DR) group. The vaccination rates among patients in each group were compared.
Results
Patients with high risk of pneumonia showed 11.2% rate for PCV13 vaccination upon their first visit; however, this rate increased to 39.2% following counseling (P<0.001). Variation among the three groups was as follows: 9.0% in the B group, 20.0% in the B+Br group, and 75.0% in the B+Br+DR group (P<0.001). After adjusting for age, sex, high-risk group, occupation, and residence, a regression analysis was carried out. The odds ratio for the PCV13 vaccination rate compared to the B group was 2.49 (95% confidence interval [CI], 0.55-11.34) for the B+Br group and 43.72 (95% CI, 11.52-165.96) for the B+Br+DR group.
Conclusions
Among the available methods, we are thought to be more effective to add doctor's verbal recommendation in a clinical setting.

Keyword

Vaccination; 13-valent pneumococcal vaccine; Pneumonia; Directive counseling; Health education

Figure

• 

  Figure 1. Study population and divided into recommendation method. PCV13, 13-valent conjugate vaccine.

• 

  Figure 2. Vaccination rates by intervention method among patients with vaccination needs. P-values were represented by chi-square test. B, banner; Br, brochure; DR, doctor’s verbal recommendation.

• 

  Figure 3. Recommendation methods (%) among PCV13 vaccinated patients in each risk group. B, banner; Br, brochure; DR, doctor’s verbal recommendation; PCV13, 13-valent conjugate vaccine. *Represents P-value <0.001 compared to non-vaccination group by chi-square test. †,‡Represent P-value 0.001, 0.004 compared to non-vaccination group by Fisher’s exact test, respectively

Reference

1. Statistics Korea. Causes of death statistics in 2018 [Internet]. Daejeon: Statistics Korea;2019. [Accessed 2020 Feb 16]. Available from: http://kostat.go.kr/portal/eng/pressReleases/8/1/index.board?bmode=read&bSeq=&aSeq=378787&pageNo=1&rowNum=10&navCount=10&currPg=&searchInfo=&sTarget=title&sTxt=.

2. Van Hoek AJ, Andrews N, Waight PA, Stowe J, Gates P, George R, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect. 2012; 65(1):17–24.

3. Kyaw MH, Rose CE Jr, Fry AM, Singleton JA, Moore Z, Zell ER, et al. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis. 2005; 192(3):377–86.

4. Kim JE, Kim UJ, Kim HK, Cho SK, An JH, Kang SJ, et al. Predictors of viral pneumonia in patients with community-acquired pneumonia. PLoS One. 2014; 9(12):e114710.

5. Kim SH, Bae IK, Park D, Lee K, Kim NY, Song SA, et al. Serotype distribution and antimicrobial resistance of streptococcus pneumoniae isolates causing invasive and noninvasive pneumococcal diseases in Korea from 2008 to 2014. Biomed Res Int. 2016; 2016:6950482.

6. The Korean Society of Infectious Diseases. Recommended adult immunization schedule (2019) [Internet]. Seoul: The Korean Society of Infectious Diseases;2019. [Accessed 2020 Feb 16]. Available from: http://www.ksid.or.kr/data/sub07.html.

7. Lau D, Hu J, Majumdar SR, Storie DA, Rees SE, Johnson JA. Interventions to improve influenza and pneumococcal vaccination rates among community-dwelling adults: a systematic review and meta-analysis. Ann Fam Med. 2012; 10(6):538–46.

8. Wiley KE, Massey PD, Cooper SC, Wood N, Quinn HE, Leask J. Pregnant women’s intention to take up a post-partum pertussis vaccine, and their willingness to take up the vaccine while pregnant: a cross sectional survey. Vaccine. 2013; 31(37):3972–8.

9. Paterson P, Meurice F, Stanberry LR, Glismann S, Rosenthal SL, Larson HJ. Vaccine hesitancy and healthcare providers. Vaccine. 2016; 34(52):6700–6.

10. Lane S, MacDonald NE, Marti M, Dumolard L. Vaccine hesitancy around the globe: analysis of three years of WHO/UNICEF Joint Reporting Form data-2015-2017. Vaccine. 2018; 36(26):3861–7.

11. Freedman MS, Hunter P, Ault K, Kroger A. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older - United States, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(5):133–5.

12. Statistics Korea. The Korean standard classification of occupations (KSCO) [Internet]. Daejeon: Statistics Korea;;2017. [Accessed 2020 Feb 16]. Available from: https://kssc.kostat.go.kr:8443/ksscNew_web/ekssc/main/main.do.

13. Lu PJ, Srivastav A, Amaya A, Dever JA, Roycroft J, Kurtz MS, et al. Association of provider recommendation and offer and influenza vaccination among adults aged ≥18 years - United States. Vaccine. 2018; 36(6):890–8.

14. Honkanen PO, Keistinen T, Kivela SL. Factors associated with influenza vaccination coverage among the elderly: role of health care personnel. Public Health. 1996; 110(3):163–8.

15. Tung WC, Lu M, Langowski J, Qiu X. Reasons and influential recommendations associated with HPV vaccination among Chinese college students in the USA. J Am Coll Health. 2020; 16:1–8.

16. Sakamoto A, Chanyasanha C, Sujirarat D, Matsumoto N, Nakazato M. Factors associated with pneumococcal vaccination in elderly people: a cross-sectional study among elderly club members in Miyakonojo city, Japan. BMC Public Health. 2018; 18(1):1172.

17. Machado A, Kislaya I, Santos AJ, Gaio V, Gil AP, Barreto M, et al. Factors associated to repeated influenza vaccination in the Portuguese adults with chronic conditions. Vaccine. 2018; 36(35):5265–72.

18. Monier A, Puyade M, Hernanz MPG, Bouchaert P, Leleu X, Tourani JM, et al. Observational study of vaccination in cancer patients: how can vaccine coverage be improved? Med Mal Infect. 2020; 50(3):263–8.

19. Song JY, Cheong HJ, Heo JY, Noh JY, Seo YB, Kim IS, et al. Outpatient-based pneumococcal vaccine campaign and survey of perceptions about pneumococcal vaccination in patients and doctors. Yonsei Med J. 2013; 54(2):469–75.

20. Meharry PM, Cusson RM, Stiller R, Vázquez M. Maternal influenza vaccination: evaluation of a patient-centered pamphlet designed to increase uptake in pregnancy. Matern Child Health J. 2014; 18(5):1205–14.

21. Lieu TA, Glauber JH, Fuentes-Afflick E, Lo B. Effects of vaccine information pamphlets on parents’ attitudes. Arch Pediatr Adolesc Med. 1994; 148(9):921–5.

22. Choi W, Kim JG, Beom SH, Hwang JE, Shim HJ, Cho SH, et al. Immunogenicity and optimal timing of 13-valent pneumococcal conjugate vaccination during adjuvant chemotherapy in gastric and colorectal cancer: a randomized controlled trial. Cancer Res Treat. 2020; 52(1):246–53.

23. Hung TY, Kotecha RS, Blyth CC, Steed SK, Thornton RB, Ryan AL, et al. Immunogenicity and safety of single-dose, 13-valent pneumococcal conjugate vaccine in pediatric and adolescent oncology patients. Cancer. 2017; 123(21):4215–23.

24. Jones LG, Zhang Y, Ahmed MI, Ekundayo OJ, Akhter S, Sawyer P, et al. Understanding the reasons for the underuse of pneumococcal vaccination by community-dwelling older African Americans. J Am Geriatr Soc. 2010; 58(12):2323–8.